Edition:
United Kingdom

Esperion Therapeutics Inc (ESPR.OQ)

ESPR.OQ on NASDAQ Stock Exchange Global Market

58.38USD
15 Dec 2017
Change (% chg)

$0.62 (+1.07%)
Prev Close
$57.76
Open
$57.98
Day's High
$58.85
Day's Low
$56.89
Volume
480,793
Avg. Vol
222,492
52-wk High
$65.18
52-wk Low
$10.74

Latest Key Developments (Source: Significant Developments)

Esperion Therapeutics Q3 loss per share $1.86‍​
Tuesday, 7 Nov 2017 

Nov 7 (Reuters) - Esperion Therapeutics Inc :Esperion provides bempedoic acid franchise development program updates; reports third quarter 2017 financial results.Expects full-year 2017 net cash used in operating activities to be approximately $135 million​.Expects cash and cash equivalents and investment securities to be approximately $272 million at December 31.Estimates cash resources are sufficient to fund operations through Q1 2020​.Qtrly loss per share $1.86‍​.Q3 earnings per share view $-1.78 -- Thomson Reuters I/B/E/S.  Full Article

Esperion announces initiation of pivotal late stage study for bempedoic acid
Monday, 6 Nov 2017 

Nov 6 (Reuters) - Esperion Therapeutics Inc :Esperion announces initiation of pivotal late stage study for the bempedoic acid / ezetimibe combination pill.Esperion Therapeutics - ‍NDA submission for LDL-C lowering indication for bempedoic acid / ezetimibe combination pill expected by Q1 2019​.Esperion Therapeutics Inc - ‍top-line results expected by q4 of 2018 for bempedoic acid / ezetimibe combination pill​.  Full Article

Meditor Group Ltd reports 8.2 pct passive stake in Esperion Therapeutics Inc
Monday, 21 Aug 2017 

Aug 21 (Reuters) - Esperion Therapeutics Inc ::Meditor Group Ltd reports 8.2 percent passive stake in Esperion Therapeutics Inc as on Aug 10 - SEC filing​.  Full Article

BB Biotech reports 5.1 pct passive stake in Esperion Therapeutics
Tuesday, 27 Sep 2016 

Esperion Therapeutics Inc :BB Biotech AG reports 5.1 pct passive stake in Esperion Therapeutics as of September 22, 2016 - SEC filing.  Full Article

Esperion Therapeutics reports Q2 net loss of $14 mln
Thursday, 4 Aug 2016 

Esperion Therapeutics Inc : Estimates current cash resources are sufficient to fund operations into 2019 . Esperion Therapeutics provides bempedoic acid development program updates; reports second quarter 2016 financial results . Esperion had a net loss of $14.0 million for q2 of 2016 compared to $12.4 million .Esperion expects full-year 2016 net cash used in operating activities in 2016 will be approximately $65 to $75 million.  Full Article

Esperion Therapeutics provides regulatory update for Bempedoic Acid
Tuesday, 28 Jun 2016 

Esperion Therapeutics Inc : Esperion Therapeutics Inc says intends to initiate planned CVOT in statin intolerant patients who are at high risk for CV disease in Q4 of 2016 . Esperion expects full-year 2016 net cash used in operating activities to be between $65 to $75 million . Expects full-year 2016 cash and cash equivalents and investment securities to be approximately $220 million at December 31, 2016 . Current cash resources are expected to be sufficient to fund operations into early 2019 .Esperion Therapeutics provides clinical development and regulatory update for bempedoic acid.  Full Article

Esperion Therapeutics announces initiation of phase 2 Clinical Study of Bempedoic Acid in Patients Treated With High-Dose Statin Therapy
Tuesday, 12 Jan 2016 

Esperion Therapeutics Inc:Announced initiation of its Phase 2 pharmacokinetics/pharmacodynamics (PK/PD) study (ETC-1002-035) of bempedoic acid in patients treated with atorvastatin 80 mg, the most commonly prescribed high-dose statin.Expects to announce top-line results from the study by mid-year.  Full Article

BRIEF-Esperion Announces The Appointment Of Jeffrey Berkowitz To Board Of Directors

* ESPERION ANNOUNCES THE APPOINTMENT OF JEFFREY BERKOWITZ TO BOARD OF DIRECTORS Source text for Eikon: Further company coverage: